Nivolumab in combination with ipilimumab for treating advanced melanoma

  • Technology appraisal guidance
  • TA400
  • Published: 
Download guidance (PDF)

3 Evidence

3.1 The appraisal committee (section 6) considered evidence submitted by Bristol-Myers Squibb together with a review of the company submission by the evidence review group (ERG). It also considered evidence received from patient and professional groups. Full details of the evidence are available.